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Oral Presentations S181were ‘‘alive and engrafted’’ mixed-chimerism (.5% recipient) at
latest follow up time point (median 57mths: 6-140) was found in
21%. The highest rate of full donor chimerism was found in uCB
(93%), compared to 73% in MSD, 64% in UD and 75% in TCDud.
Normal enzyme levels at latest follow up time point were found in all
(100%) of the uCB, in 53% of MSD, in 74% of UD and in 75% of
TCDud recipients.
Outcomes following SCT is HS are encouraging. Younger age at
SCT is a predictor for higher OS. Regarding OS, MSD do better
compared to UD and uCB, but no difference was found for EFS.
TCDud is a predictor for lower OS/EFS. uCB leads to higher donor-
chimerism levels and enzymes which is suggested to have a positive
impact on the long term outcomes.69
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Background: Long-term EFS in CAYA with poor risk HL who
are induction failures or who relapse or progress following initial
therapy is poor (#30% 10 year EFS) due to relapse and secondary
MDS or malignancy (Bradley/Cairo et al., BMT, 2008). Recent
data in poor risk adult HL suggests a strong GVHL effect follow-
ing RIC AlloSCT (Peggs et al., Lancet, 2005 and Sureda et al.,
JCO, 2008). A recent review by the EBMT reports encouraging
results in 51 children and adolescents with chemosensitive HL
who received RIC AlloSCT (Claviez et al., Blood, 2009). How-
ever, 63% of these patients had already failed MAC AutoSCT,
reducing the number of pts who were chemosensitive prior to
RIC AlloSCT.
Objective: We prospectively evaluated the safety and efficacy of
MAC AutoSCT followed by RIC AlloSCT in CAYA with poor-
risk HL.
Methods: Poor-risk HL pts achieving CR, PR, or SD after re-induc-
tion were eligible to receive CBV conditioning (Harris/Cairo, ASH,
2004) followed by RIC with busulfan (6.4 mg/kg), fludarabine
(180 mg/m2)6R-ATG (forunrelated SCT).GVHD prophylaxis con-
sisted of MMF and tacrolimus as we have previously described
(Osunkwo/Cairo et al., BBMT, 2004), with discontinuation of MMF
on day 30/60 (related/unrelated AlloSCT) and a 4-6 week tacrolimus
taper.
Results: Ten pts, median age 18.4 (range 12.3-21.8), M/F 6/4 and
disease status at MAC AutoSCT CR (5), PR (3), SD (2). Two refused
RIC AlloSCT; of the 8 allografts, 1 related/7 unrelated, 5 UCBT/3
PBSC, HLA matching 6/6 (1), 5/6 (1), 4/6 (5), 8/10 (1), median TNC
dose 0.35108/kg (0.09-6.13) and CD34 0.59106/kg (0.04-5.30).
All pts (n5 8) engrafted neutrophils following RIC AlloSCT at
median day 19 (15-45). Six of 7 evaluable pts engrafted platelets at
median day 46 (11-170). The probability of $grade II acute
GVHD was 37.5% (95% CI 0-63%) and of chronic GVHD 30%
(0-58%). Patients achieved median percent donor chimerism of
100%, 100% and 98%, on days 100, 180 and 365, respectively. Prob-
abilities of 1-year and 2-year OS (all, n5 10) were 90% (73-100%)
and 80% (59-100%) respectively. Three pts died on days 338, 370
and 746 of varicella, progressive HL and chronic GVHD/aspergillo-
sis, respectively. Seven pts are currently living at a median follow-up
of 2191 days.
Conclusions MAC AutoSCT followed by RIC AlloSCT for CAYA
with poor-risk HL is feasible and results in excellent early OS. Long-
term follow-up and a larger cohort are needed to determine whether
this approach improves 10-year EFS compared to MAC AutoSCT
alone.70
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Background: Complex autoimmune enteropathies encompass
a wide range of disorders including X-linked immune dysregulation,
polyendocrinopathy, enteropathy (IPEX) syndrome with FOXP3
gene mutation, IPEX-like syndrome (similar features as IPEX with-
out gene mutation) and other unclassified autoimmune enteropa-
thies.
Method: A retrospective study of patients with complex autoim-
mune enteropathies who underwent hematopoeitic stem cell trans-
plantation (HSCT) at Newcastle General Hospital, one of two
nationally designated centres for such procedures in the UK, was
performed.
Results: 13 patients were identified who fulfilled the inclusion crite-
ria; 2 (15%) IPEX, 8 (62%) IPEX-like and 3 (23%) unclassified au-
toimmune enteropathy. Median age at the time of HSCT was 2.5
years, ranged between 5 months to 19.5 years old. 9/13 (69%) pa-
tients were male. All underwent HSCT with 10/13 (77%) unrelated
(URD) including 3 cord transplant, and 3/13 (23%) matched sibling
(MSD). The conditioning regimen used was Fludarabine/Melphalan
in 6 (46.2%), Busulfan/Cyclophosphamide in 3 (23%), Treosulfan/
Cyclophosphamide in 2 (15.4%) and Treosulfan/Fludarabine in 2
(15.4%). 100% donor chimerism was achieved in 10 (77%) patients
including one after the unconditioned boost infusion 27 days post
HSCT. 3 (23%) patients have mixed donor chimerism with 60%
donor T cells. Ten (80%) patients are alive with resolution of enter-
opathy and have discontinued immunosuppression, one remains an
inpatient after HSCT about 100 days ago. 5/13 (38%) patients had
no graft versus host disease (GvHD) and 6/13 (46%) had only grade
II-III skin GvHD. Two (15%) died from complications related to
treatment of grade III skin and gut GvHD.
Conclusion: HSCT can be curative in patients with severe complex
autoimmune enteropathy. GvHD is a common significant complica-
tion which can be life threatening.71
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Objective: To examine the feasibility, safety and efficacy of he-
matopoietic stem cell transplantation (HSCT) in high-risk pedi-
atric and adult patients with chronic granulomatous disease
(CGD) using a low-toxicity conditioning regimen based on
half-dosed (50-60%) Busulfan, full-dose Fludarabine and in-vivo
T-cell depletion.
Patients andMethods: 11 CGD patients (5, 7, 12, 13, 17, 18, 20, 23,
29, 35 and 39 ys; n5 8 gp91-phox, n5 2 p22-phox and n5 1 p47
phox deficient) are described. All patients were therapy-refractory
to conventional treatment suffering from infectious and/or inflam-
matory complications at HSCT, e.g. colitis, active infection (Asper-
gillus, Neisseria, Actinomyces, Staph. aureus) or had former lung
aspergillosis. Stem cell donors consisted of 5 matched sibling, 4
MUD (10/10) and 2 MMUD (9/10) donors. Conditioning included
180 mg/qm Fludarabine (d -8 to -3), oral/iv. Busulfan (6.4-12 mg/
kg; d -4 to -2; in pediatric patients with adjusted Busulfan kinetics)
and Antithymocyte-Globulin Fresenius (4  10 mg/kg; d -4 to -1).
In 4 patients (5, 7, 12 and 17 ys) receiving MUD or MMUD trans-
plants, ATG-Fresenius was replaced by 0.5 mg/kg Alemtuzumab
(Campath IH) (d -8 to -6). As stem cell source, bone marrow (2.3
to 6.0  10 6 CD34/kg) was used in the majority of cases (n5 10),
